Citi Appointed as Successor Depositary Bank for ANGLE’s ADR Programme
May 01 2020 - 7:08AM
Business Wire
Citi, acting through Citibank N.A., has been appointed by ANGLE
plc (“ANGLE”) – a world-leading liquid biopsy company – to act as
successor depositary bank for its American Depositary Receipt
(“ADR”) programme.
ANGLE’s American Depositary Shares (“ADS”) trade on the OTCQX
market under the symbol “ANPCY”. Each ADS represents 10 ordinary
shares of the company. ANGLE’s underlying ordinary shares are
listed and trade on London Stock Exchange AIM market under the
symbol “AGL”.
Commenting on the appointment, Dirk Jones, Global Head of Issuer
Services, at Citi said: “We look forward to supporting ANGLE’s ADR
programme and expanding the company’s investor outreach through the
expertise of our leading Investor Relations Advisory team and the
breadth of our global equity distribution network.”
For more information on Citi’s Depositary Receipt Services,
visit www.citi.com/dr.
About ANGLE www.angleplc.com
ANGLE is a world leading liquid biopsy company with
sample-to-answer solutions. ANGLE's proven patent protected
platforms include a circulating tumor cell (CTC) harvesting
technology and a downstream analysis system for cost effective,
highly multiplexed analysis of nucleic acids and proteins.
ANGLE's cell separation technology is called the Parsortix®
system, and it enables a liquid biopsy (a simple blood test) to be
used to provide cells of interest to users in a format suitable for
multiple types of downstream analyses. The system uses a
microfluidic device that captures cells based on a combination of
their size and compressibility. The system is epitope independent
and can capture all types of CTCs as well as CTC clusters in a
viable form (alive). CTCs enable the complete picture of a cancer
to be seen, as being a complete cell allows DNA, RNA and protein
analysis, and the live cells harvested can also be cultured. The
Parsortix technology is the subject of 24 granted patents in
Europe, the United States, China, Australia, Canada, India, Japan
and Mexico with three extensive families of patents are being
progressed worldwide. The Parsortix system has a CE Mark in Europe
for the indicated use and submission to FDA for clearance is in
process for the United States using results from two separate
clinical studies of over 250 metastatic breast cancer patients and
associated analytical studies. ANGLE is seeking to be the first
ever FDA cleared CTC harvesting system and only the third ever FDA
cleared liquid biopsy test. ANGLE has already undertaken two
separate 200 subject clinical studies under a program designed to
develop an ovarian cancer pelvic mass triage test, with the results
showing best in class accuracy (ROC-AUC) of 95.1%. The pelvic mass
triage assay has undergone further refinement and optimisation, and
is currently in the process of a 200 patient clinical verification
study.
ANGLE's technology for the multiplex evaluation of proteins and
nucleic acids of all types is called the HyCEADTM Ziplex® platform
and is based on a patented flow through array technology. It
provides for low cost, highly multiplexed, rapid and sensitive
capture of targets from a wide variety of sample types. A
proprietary chemistry approach (the HyCEAD method) allows for the
capture and amplification of over 100 biomarkers simultaneously in
a single reaction. The HyCEAD Ziplex system is extremely sensitive
and is ideal for measuring gene expression and other markers
directly from Parsortix harvests and was used in the ovarian cancer
pelvic mass triage test to achieve best in class accuracy (ROC-AUC)
of 95.1%.
ANGLE's proprietary technologies can be combined to provide
automated, sample-to-answer results in both centralised laboratory
and point-of-use cartridge formats.
ANGLE has established formal collaborations with world-class
cancer centres and major corporates such as Abbott, Philips and
QIAGEN, and works closely with leading CTC translational research
customers. These Key Opinion Leaders (KOLs) are working to identify
applications with medical utility (clear benefit to patients), and
to secure clinical data that demonstrates that utility in patient
studies. The body of evidence as to the benefits of the Parsortix
system is growing rapidly from our own clinical studies in
metastatic breast cancer and ovarian cancer and also from KOLs with
31 peer-reviewed publications and numerous publicly available
posters, available on our website.
About Citi Citi, the leading global bank, has
approximately 200 million customer accounts and does business in
more than 160 countries and jurisdictions. Citi provides consumers,
corporations, governments and institutions with a broad range of
financial products and services, including consumer banking and
credit, corporate and investment banking, securities brokerage,
transaction services, and wealth management.
Additional information may be found at www.citigroup.com |
Twitter: @Citi | YouTube: www.youtube.com/citi | Blog:
http://blog.citigroup.com | Facebook: www.facebook.com/citi |
LinkedIn: www.linkedin.com/company/citi
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200501005248/en/
Citi Media Contacts: Susan Monahan +44 (0) 20 7508 0786
susan.monahan@citi.com ANGLE Investor Contacts: Andrew
Newland, Chief Executive Ian Griffiths, Finance Director +44 (0)
1483 343434
Citigroup (NYSE:C)
Historical Stock Chart
From Aug 2024 to Sep 2024
Citigroup (NYSE:C)
Historical Stock Chart
From Sep 2023 to Sep 2024